- Pen upgraded Biogen Inc BIIB of Hold to Buy and said stocks have faded since positive lecanemab data in mild Alzheimer’s disease.
- It lifted the Price target from $223 to $299.
- The analyst is concerned about remaining competitive/business risks notwithstanding the uncertainty surrounding Biogen’s future CEO.
- Stifel views are coming Roche Holding Ltd RHHBY The gantenerumab data is unlikely to meet the high bar recently set by lecanemab, and believes lecanemab has a significant commercial role even if it does Eli Lilly and Co LLY Donanemab is successful due to lecanemab’s much lower ARIA rate.
- Related: These stocks are on the radar after Biogen-Eisai’s surprise win in Alzheimer’s lawsuit.
- In the short-term, in the most likely gantenerumab data scenarios, Stifel’s analyst believes shares of Biogen will trade higher.
- It should be noted that the stock setup is admittedly difficult and the risk/reward tradeoff is tilted to the upside as there is more skepticism than expected about a best-case scenario for CLARITY-AD.
- So does lecanemab, according to a recent research report Patient benefit may be limited.
- Price promotion: BIIB shares are up 7.04% on the last check Thursday to $271.54.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
